Page 253 - 2020_01-Haematologica-web

Targeting CARVs using ex-vivo-expanded VSTs
References
1. Hodinka RL. Respiratory RNA Viruses. Microbiol Spectr. 2016;4(4).
2. Gill PJ, Richardson SE, Ostrow O, et al. Testing for Respiratory Viruses in Children: To Swab or Not to Swab. JAMA Pediatr. 2017;171(8):798-804.
3. Nair H, Simoes EA, Rudan I, et al. Global and regional burden of hospital admissions for severe acute lower respiratory infec- tions in young children in 2010: a systemat- ic analysis. Lancet. 2013;381(9875):1380- 1390.
4. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease bur- den estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017; 390(10098):946-958.
5. Paulsen GC, Danziger-Isakov L. Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation. Clin Chest Med. 2017; 38(4):707-726.
6. Abbas S, Raybould JE, Sastry S, et al. Respiratory viruses in transplant recipients: more than just a cold. Clinical syndromes and infection prevention principles. Int J Infect Dis. 2017;62:86-93.
7. Hutspardol S, Essa M, Richardson S, et al. Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015;21(10):1802-1807.
8. Lin R, Liu Q. Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2013;6:94.
9. Renaud C, Xie H, Seo S, et al. Mortality rates of human metapneumovirus and res- piratory syncytial virus lower respiratory tract infections in hematopoietic cell trans- plantation recipients. Biol Blood Marrow Transplant. 2013;19(8):1220-1226.
10. Shah DP, Shah PK, Azzi JM, et al. Human metapneumovirus infections in hematopoi- etic cell transplant recipients and hemato- logic malignancy patients: A systematic review. Cancer Lett. 2016;379(1):100-106.
11. Shah DP, Shah PK, Azzi JM, et al. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A sys- tematic review. Cancer Lett. 2016; 370(2):358-364.
12. Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;59 Suppl 5:S344-351.
13. Beaird OE, Freifeld A, Ison MG, et al. Current practices for treatment of respira- tory syncytial virus and other non-influen- za respiratory viruses in high-risk patient
populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis. 2016; 18(2):210-215.
14. Chemaly RF, Aitken SL, Wolfe CR, et al. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis. 2016;18(4):634-636.
15. Griffiths C, Drews SJ, Marchant DJ. Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clin Microbiol Rev. 2017;30(1):277-319.
16. Walsh EE. Respiratory Syncytial Virus Infection: An Illness for All Ages. Clin Chest Med. 2017;38(1):29-36.
17. Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra83.
18. Tzannou I, Papadopoulou A, Naik S, et al. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017;35(31):3547-3557.
19. Aguayo-Hiraldo PI, Arasaratnam RJ, Tzannou I, et al. Characterizing the cellular immune response to parainfluenza virus 3. J Infect Dis. 2017; 216(2):153-161.
20. Gerdemann U, Keirnan JM, Katari UL, et al. Rapidly generated multivirus-specific cyto- toxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012;20(8):1622-1632.
21. Tzannou I, Nicholas SK, Lulla P, et al. Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy. J Infect Dis. 2017;216(6):678-687.
22. Goka E, Vallely P, Mutton K, et al. Influenza A viruses dual and multiple infections with other respiratory viruses and risk of hospi- talisation and mortality. Influenza Other Respir Viruses. 2013;7(6):1079-1087.
23. Goka EA, Vallely PJ, Mutton KJ, et al. Single, dual and multiple respiratory virus infections and risk of hospitalization and mortality. Epidemiol Infect. 2015;143(1):37- 47.
24. Kouni S, Karakitsos P, Chranioti A, et al. Evaluation of viral co-infections in hospital- ized and non-hospitalized children with respiratory infections using microarrays. Clin Microbiol Infect. 2013;19(8):772-777.
25. Lim FJ, de Klerk N, Blyth CC, et al. Systematic review and meta-analysis of respiratory viral coinfections in children. Respirology. 2016;21(4):648-655.
26. Stefanska I, Romanowska M, Donevski S, et al. Co-infections with influenza and other respiratory viruses. Adv Exp Med Biol. 2013;756:291-301.
27. Salvatore M, Satlin MJ, Jacobs SE, et al. DAS181 for treatment of parainfluenza Virus infections in hematopoietic stem cell Transplant recipients at a single center. Biol
Blood Marrow Transplant. 2016;22(5):965-
970.
28. Zenilman JM, Fuchs EJ, Hendrix CW, et al.
Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults. Antiviral Res. 2015;123:114-119.
29. Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoiet- ic cell transplant recipients: factors deter- mining progression to lower respiratory tract disease. J Infect Dis. 2014;209(8):1195- 1204.
30. Vakil E, Sheshadri A, Faiz SA, et al. Risk factors for mortality after respiratory syn- cytial virus lower respiratory tract infection in adults with hematologic malignancies. Transpl Infect Dis. 2018;20(6):e12994.
31. Gerdemann U, Katari UL, Papadopoulou A, et al. Safety and clinical efficacy of rapidly- generated trivirus-directed T cells as treat- ment for adenovirus, EBV, and CMV infec- tions after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013;21(11):2113- 2121.
32. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925-935.
33. Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats aden- ovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009; 114(19):4283-4292.
34. Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biop- sy-proven EBV+ lymphomas after allogene- ic hematopoietic cell transplantation. Blood. 2012;119(11):2644-2656.
35. Feucht J, Opherk K, Lang P, et al. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood. 2015; 125(12):1986-1994.
36. Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010; 116(20):4360-4367.
37. Peggs KS, Verfuerth S, Pizzey A, et al. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity fol- lowing allogeneic stem cell transplantation. Clin Infect Dis. 2009;49(12):1851-1860.
38. Chen L, Zanker D, Xiao K, et al. Immunodominant CD4+ T-cell responses to influenza A virus in healthy individuals focus on matrix 1 and nucleoprotein. J Virol. 2014;88(20):11760-11773.
39. Grant EJ, Quinones-Parra SM, Clemens EB, et al. Human influenza viruses and CD8(+) T cell responses. Curr Opin Virol. 2016; 16:132-142.
haematologica | 2020; 105(1)
243